

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	secukinumab
Cosentyx™	Cosentyx™
Dosage Form(s)	150 mg/ml solution for injection
Manufacturer	Novartis Pharmaceuticals Canada Inc.
Submission Type	New Submission
Use Reviewed	Moderate to severe plaque psoriasis
Common Drug Review (CDR)	Yes, CDR recommended: to List with criteria . Visit the CDR website for more details: https://www.cadth.ca/sites/default/files/cdr/complete/SR0407_Cosentyx_Oct-30-15.pdf
Drug Benefit Council (DBC) or Provincial Review	DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the Canadian Drug Expert Committee (CDEC) recommendation and an internal review only. The DBC screened secukinumab (Cosentyx™) and advised that because secukinumab (Cosentyx™) is similar to some of the other drugs used for the treatment of plaque psoriasis, the Ministry may accept the CDEC's recommendation for secukinumab (Cosentyx™).
Drug Coverage Decision	Limited Coverage Benefit . Access the secukinumab criteria from www.gov.bc.ca/pharmacarespecialauthority
Date	July 28, 2016
Reason(s)	The Ministry reviewed clinical evidence and pharmacoeconomic reports prepared by the CDR, and the Final CDEC Recommendation. Patient input was collected through Your Voice but no input was received. <ul style="list-style-type: none"> • Secukinumab demonstrated some efficacy advantage compared to placebo and etanercept. • The Ministry participated in the pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with manufacturer for secukinumab, and the participating jurisdictions were able to reach an agreement with the manufacturer.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) (DBC) gives advice to the Ministry. The DBC looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. [Drug Review Process](#) and [PharmaCare](#) program for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.